Celgene Added To US 1 List At Bank Of America

Celgene Corporation CELG was added to Bank of America's US 1 List Monday morning, reflecting strong annual revenue and EPS growth.

The firm expects continued strong Revlimid growth momentum and a likely patent settlement, which would remove an overhang. Shares are Buy rated with a $112 price target. This is on the heels of a solid earnings report last week.

Shares of Celgene have moved from $84 on October 16 to all-time highs of $105.25 at time of publication, a 25 percent move.